Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Josep Rodés-Cabau Added: 5 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device… View more
Author(s): Marat Fudim , David Duncker Added: 2 months ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19… View more
Author(s): Mayra Guerrero Added: 5 months ago
Gain essential insights into the pivotal trials and procedural techniques shaping transcatheter mitral valve replacement with Dr Mayra GuerreroThis presentation, part of Women As One's comprehensive Structural Interventions track, provides timely analysis of the landmark SUMMIT and ENCIRCLE trials that are defining the future of dedicated mitral devices.Drawing from clinical trial data showing… View more
Author(s): Ignacio Inglessis-Azuaje Added: 5 months ago
Navigate the complexities of patient selection and device matching in TMVR with Dr Ignacio Inglessis-AzuajeThis presentation, part of Women As One's comprehensive Structural Interventions track, provides essential guidance for clinicians approaching this rapidly evolving field. The presentation systematically explores general eligibility requirements including symptomatic severity, surgical risk… View more
Author(s): Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more